A Dermatologist Asks the Question Everyone Should Be Asking
Peptides are everywhere right now. They are in your skincare products, in your gym buddy's supplement stack, in conversation with your doctor, and all over social media. But do they actually work? Dr. Sarah Sheu, a board-certified dermatologist, pulls apart the evidence for peptides across multiple applications, from anti-aging skincare to injectable performance peptides, and gives her honest assessment of where the science stands versus where the marketing has run ahead of it.
Her starting point is useful: not all peptides are the same. The word "peptide" describes a category, not a specific compound. It is like saying "supplement" or "drug." Within that category, you have hundreds of different molecules with different structures, different mechanisms, and wildly different levels of evidence behind them. Copper peptides in your face serum have nothing in common with BPC-157 injections except the basic chemical classification. Evaluating "peptides" as a single category makes about as much sense as evaluating "food" as a single category. You have to look at each one individually.
Topical Peptides in Skincare: What Holds Up
Dr. Sheu spends the first portion of her analysis on topical peptides, which is her primary domain as a dermatologist. The skincare industry has embraced peptides aggressively, and the claims range from modest to absurd. She separates the peptides that have reasonable evidence from the ones that are mostly marketing.
Copper peptides (GHK-Cu) have the strongest evidence base in topical skincare. Multiple studies have shown that copper peptide formulations can stimulate collagen production, improve skin elasticity, and reduce the appearance of fine lines. A 2015 study in the Journal of Cosmetic Dermatology found that a GHK-Cu cream applied twice daily for 12 weeks produced measurable increases in collagen density on ultrasound. The effect is real, though it is modest compared to what you would get from retinoids or professional procedures like microneedling.
Matrixyl (palmitoyl pentapeptide-4) is another topical peptide with decent evidence. It signals skin cells to produce more collagen and has been shown in clinical studies to reduce wrinkle depth over 6 to 12 months of consistent use. Dr. Sheu notes that Matrixyl studies are not as robust as retinoid studies, with smaller sample sizes and often industry funding, but the evidence is positive enough to consider it a reasonable active ingredient in an anti-aging routine.
Argireline (acetyl hexapeptide-3) is marketed as "topical Botox," which Dr. Sheu calls misleading. It does inhibit neurotransmitter release at the muscular junction, similar in concept to botulinum toxin, but the degree of effect is far smaller. Studies show modest wrinkle improvement with consistent use, but nothing approaching what injectable neuromodulators achieve. If you set your expectations appropriately, it is a fine ingredient. If you expect Botox-level results from a cream, you will be disappointed.
The skincare peptides that Dr. Sheu is less enthusiastic about are the ones with minimal published evidence and maximum marketing claims. She names a few specific products (which we will not repeat here) that use proprietary peptide blends at undisclosed concentrations, making it impossible to evaluate whether the product contains enough active ingredient to do anything. Her advice: if a company will not tell you the concentration of the peptide in their product, be skeptical about the product claims.
Injectable Peptides: Where It Gets Interesting and Complicated
The second half of the video shifts to injectable peptides used for performance, recovery, and anti-aging. This is where Dr. Sheu steps slightly outside her primary specialty but brings a scientist's eye to the evidence evaluation. She covers BPC-157, growth hormone secretagogues (CJC-1295 and Ipamorelin), and some of the newer entries like MOTS-c and humanin.
Her assessment of BPC-157 mirrors what many evidence-based physicians have said: the preclinical data in animal models is impressively consistent, with studies showing accelerated healing of tendons, ligaments, muscles, and gut tissue. But human clinical trials are scarce, small, and not yet sufficient to make definitive claims. She describes the evidence as "strong enough to be interesting, not strong enough to be certain." That feels like an honest and accurate summary of where things stand.
For growth hormone secretagogues, she notes that the mechanism is well-understood (stimulating your pituitary to release more growth hormone) and that elevated growth hormone and IGF-1 levels can improve body composition, recovery, and skin quality. The concern she raises is about the long-term safety of chronically elevated growth hormone levels. GH is not an uncomplicated good. Higher IGF-1 levels have been associated with increased cancer risk in epidemiological studies, though the causal relationship is not fully established. She recommends regular bloodwork monitoring for anyone using these peptides, with IGF-1 levels tracked every 8 to 12 weeks.
MOTS-c and humanin are mitochondrial-derived peptides that have shown promising effects on metabolic health and cellular aging in animal models. Dr. Sheu describes them as the "next frontier" of peptide research but notes that human evidence is extremely early. These are compounds to watch, not compounds to build a protocol around yet.
The Delivery Problem That Nobody Talks About
One of the most valuable parts of this video is Dr. Sheu's discussion of bioavailability and delivery. For topical peptides, the challenge is getting the molecule through the skin barrier. Most peptides are too large to penetrate the stratum corneum effectively on their own. Formulation matters enormously. A peptide in a well-designed delivery system (liposomal encapsulation, micro-emulsion, or combined with penetration enhancers) will perform very differently from the same peptide in a basic cream or serum.
This is why Dr. Sheu cautions against assuming that all products containing the same peptide will produce the same results. The peptide itself is only half the equation. The delivery vehicle, the concentration, the pH of the formulation, and the other ingredients all affect how much active peptide actually reaches the target tissue. Two products can contain the same peptide at the same listed concentration and produce very different results because of differences in formulation chemistry.
For injectable peptides, the delivery problem is different but still real. Peptides are fragile molecules that degrade with heat, light, and time. Proper reconstitution, cold storage, and use within the recommended timeframe are all necessary for the peptide to retain its bioactivity. Buying peptides from unregulated online sources introduces additional uncertainty about purity, potency, and degradation during shipping.
The Regulatory Landscape Is Shifting Fast
Dr. Sheu touches on the regulatory environment, which is particularly relevant given the FDA's recent actions around peptides. In 2023 and 2024, the FDA moved to restrict several peptides from compounding pharmacies, arguing that they did not meet the criteria for legal compounding under current law. This has affected access to some popular peptides and created confusion about what is and is not legally available.
Her advice is practical: work with a licensed physician who sources from reputable compounding pharmacies that operate within FDA guidelines. The gray market for peptides is large and growing, but the risks of contamination, mislabeling, and degraded product are real. For topical peptides in skincare, stick with established brands that publish their ingredient concentrations and have some level of clinical testing behind their formulations.
A Framework for Evaluating Peptide Claims
Dr. Sheu ends with a framework that anyone can use when evaluating peptide products or protocols. First, identify the specific peptide and look for published research on that exact compound, not a related compound or a general category. Second, assess the quality of the evidence: randomized controlled trials in humans are the gold standard, followed by observational human data, followed by animal studies, followed by cell culture studies. Marketing claims and testimonials sit at the very bottom of the evidence hierarchy.
Third, consider the delivery method and whether it is appropriate for the peptide in question. A peptide that works when injected subcutaneously may not work when taken orally or applied topically, because the route of administration determines how much active compound reaches the target tissue. Fourth, look at the source. Is the product coming from a regulated pharmacy or manufacturer, or from an unregulated supplier? Quality control matters for compounds that are measured in micrograms.
Finally, manage your expectations. Even the peptides with the strongest evidence produce effects that are incremental, not transformational. They are tools that can support a good health and skincare routine, not replacements for the fundamentals of sleep, nutrition, sun protection, and exercise. If someone is promising you dramatic results from a peptide, they are probably selling you something rather than educating you. Dr. Sheu's overall message is optimistic but measured: the field is advancing rapidly and new clinical data is emerging for compounds that were previously only supported by preclinical evidence. Staying current with the published literature, rather than relying on social media or marketing claims, is the only reliable way to keep up. peptides do work, some of them, for some applications, when used correctly and sourced responsibly. The challenge is separating the science from the hype, and that requires asking better questions rather than accepting marketing at face value. Her framework for evaluation is worth memorizing because it applies to any health product or protocol, not just peptides.